TCGA-05-4384-01A-01R-1755-07
— · cohortA2
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA2
- subtype
- cohortA2
- age_years
- 66
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- FATTY_ACID_METABOLISM+0.330
- BILE_ACID_METABOLISM+0.320
- WNT_BETA_CATENIN_SIGNALING+0.310
- TGF_BETA_SIGNALING+0.280
- ADIPOGENESIS+0.240
- HEME_METABOLISM+0.230
- ESTROGEN_RESPONSE_EARLY+0.180
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.180
- MYOGENESIS+0.170
- XENOBIOTIC_METABOLISM+0.160
Top 10 suppressed
- E2F_TARGETS-0.690
- G2M_CHECKPOINT-0.630
- MYC_TARGETS_V2-0.550
- MYC_TARGETS_V1-0.520
- MTORC1_SIGNALING-0.450
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.440
- UNFOLDED_PROTEIN_RESPONSE-0.370
- ALLOGRAFT_REJECTION-0.350
- ANGIOGENESIS-0.350
- INTERFERON_GAMMA_RESPONSE-0.350
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-62-8395-01A-11R-2326-07 | — | cohortA2 | 0.919 |
| 2 | TCGA-73-7498-01A-12R-2187-07 | — | cohortA2 | 0.891 |
| 3 | TCGA-AC-A2FG-01A-11R-A17B-07 | — | A | 0.872 |
| 4 | C3L-00893 | — | cohortA1 | 0.871 |
| 5 | TCGA-75-6206-01A-11R-1755-07 | — | cohortA2 | 0.843 |
| 6 | TCGA-97-8174-01A-11R-2287-07 | — | cohortA2 | 0.824 |
| 7 | BS_CGB2WS2A | pilocytic astrocytoma | — | 0.822 |
| 8 | C3N-02973 | — | cohortA1 | 0.809 |
| 9 | TCGA-44-6776-01A-11R-1858-07 | — | cohortA2 | 0.808 |
| 10 | C3L-02958 | — | cohortA1 | 0.806 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 18 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| FATTY_ACID_METABOLISM | 0.330 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.320 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.310 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.280 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.240 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.230 | Temsirolimus | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.180 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.180 | Inavolisib | — uncovered |
| MYOGENESIS | 0.170 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.160 | Inavolisib | — uncovered |
| COAGULATION | 0.120 | Binimetinib | — uncovered |
| UV_RESPONSE_DN | 0.120 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.100 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.100 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.090 | Inavolisib | — uncovered |
| PEROXISOME | 0.060 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.040 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.010 | Inavolisib | — uncovered |